CDC42 and androgen insensitivity syndrome: In detail, it was found that although CDC42 in recurrent and non-recurrent patients with AIS was declined within 3 days, then exhibited a climbing trend from 3 days to 3 years, the difference in CDC42 between these two groups was gradually enlarged over time.